[logo] HealthTree Foundation
search person

Allo Transplant Tip: Skip the Azithromycin and Use Another Antibiotic

Posted: Oct 10, 2017
Allo Transplant Tip: Skip the Azithromycin and Use Another Antibiotic image

Allogeneic donor transplant have to carefully watch out for infections following transplant. A lung condition called bronchiolitis obliterans syndrome (BOS) can complicate allo transplant so an antibiotic called azithromycin was tested to counter this type of infection. Researchers recently found, however, that more patient deaths occurred on azithromycin than without. In a study called Azithromycin Increases Mortality After Hematopoietic Stem Cell Transplantation , 480 blood cancer allo transplant patients patients received either 2 years of azithromycin ((250 mg three times weekly) or placebo.

The study was stopped after 13 months when it was determined that the risk for hematologic malignancy relapse was increased with azithromycin versus placebo (33.5% vs. 22.3%; hazard ratio, 1.7; P=0.002).

Azithromycin recipients also had reduced airflow decline–free survival (the primary outcome; 32.8% vs. 41.3%; P=0.03), more cases of BOS (6% vs. 3%), and reduced 2-year survival (56.6% vs. 70.1%; P=0.02). Discontinuation rates were similarly high (>50%) in both treatment groups.

If you are an allo transplant patient, ask your doctor which antibiotics will be most protective and safe for your recovery.

Allogeneic donor transplant have to carefully watch out for infections following transplant. A lung condition called bronchiolitis obliterans syndrome (BOS) can complicate allo transplant so an antibiotic called azithromycin was tested to counter this type of infection. Researchers recently found, however, that more patient deaths occurred on azithromycin than without. In a study called Azithromycin Increases Mortality After Hematopoietic Stem Cell Transplantation , 480 blood cancer allo transplant patients patients received either 2 years of azithromycin ((250 mg three times weekly) or placebo.

The study was stopped after 13 months when it was determined that the risk for hematologic malignancy relapse was increased with azithromycin versus placebo (33.5% vs. 22.3%; hazard ratio, 1.7; P=0.002).

Azithromycin recipients also had reduced airflow decline–free survival (the primary outcome; 32.8% vs. 41.3%; P=0.03), more cases of BOS (6% vs. 3%), and reduced 2-year survival (56.6% vs. 70.1%; P=0.02). Discontinuation rates were similarly high (>50%) in both treatment groups.

If you are an allo transplant patient, ask your doctor which antibiotics will be most protective and safe for your recovery.

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

newsletter icon

Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.

Follow Us

facebook instagram linkedin tiktok youtube